New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

Sunday, October 10, 2010 - 09:20 in Health & Medicine

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with...

Read the whole article on Science Blog

More from Science Blog

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net